Periodic erythroexchange is an effective strategy for high risk paediatric patients with sickle-cell disease

Transfusion and Apheresis Science

Volumn 37, Issue 3, 2007, Pages 241-247

  Masera, Nicoletta ^a   Tavecchia, Luisa ^a   Pozzi, Lorena ^a   Riva, Francesca ^a   Vimercati, Chiara ^a   Calabria, Manuela ^a   Ronzoni, Simona ^a   Masera, Giuseppe ^a   Perseghin, Paolo ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Erythrocytapheresis; Sickle cell disease

Indexed keywords

DEFEROXAMINE; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MALE; PATIENT SAFETY; QUALITY OF LIFE; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DRUG TOLERANCE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; HYDROXYUREA; INFANT; MALE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 36549023963     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.09.005     Document Type: Article

References (28)

1. Steinberg M.H. Management of sickle cell disease. New Eng J Med 340 13 (1999) 1021-1030
2. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program; 2006. p. 48-53.
3. Wayne A.S., Kevy S.V., and Nathan D.G. Transfusion management in sickle cell disease. Blood 81 5 (1993) 1109-1123
4. Josephson C.D., Su L.L., Hillyer K.L., and Hillyer C.D. Transfusion in patients with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 21 2 (2007) 118-133
5. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 (1995) 1317-1322
6. Ware R.E., Zimmerman S.A., and Schultz W.H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94 9 (1999) 3022-3026
7. Hankins J.S., Ware R.E., Roger Z.R., Wynn L.W., Lane P.A., Scott J.P., et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106 7 (2005) 2269-2275
8. DeBaun M.R. Hydroxiurea as secondary prevention for stroke in children with sickle cell anemia. J Pediatr 147 (2005) 560-561
9. Gulbis B., Haberman D., Dufour D., Christophe C., Vermylen C., Kagambega F., et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 105 (2005) 2685-2690
10. De Franceschi L., and Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica 89 3 (2004) 348-356
11. Bakanay S.M., Dainer E., Clair B., Adekile A., Daitch L., Well L., et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 105 2 (2005) 545-547
12. Adams R.J., McKie V.C., Brambilla D., Carl E., Gallagher D., Nichols F.T., et al. Stroke prevention trial in sickle cell anemia. Control Clin Trial 19 1 (1998) 110-129
13. Cabibbo S., Fidone C., Garozzo G., Antolino A., Manenti G.O., Bennardello F., et al. Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. Transfus Apheresis Sci 32 (2005) 315-321
14. Singer S.T., Quirolo K., Nishi K., Hackney-Stephens E., Evans C., and Vichinsky E.P. Erytrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apheresis 14 (1999) 122-125
15. Hilliard L.M., Williams B.F., Lounsbury A.E., and Howard T.H. Erytrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 59 (1998) 28-35
16. Lapierre Y., Rigal D., Adam J., Josef D., Meyer F., Greber S., et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion 30 (1990) 109-113
17. Aliyu Z.Y., Tumblin A.R., and Kato G.J. Current therapy of sickle cell disease. Haematologica 91 1 (2006) 7-10
18. Roberts I., and de Montalbert M. Sickle cell disease as a paradigm of immigration haematology: new challenges for haematologist in Europe. Haematologica 92 (2007) 865-871
19. Hartwig D., Schlager F., Bucsky P., Kirchner H., and Schlenke P. Successful long-term erythrocytapheresis therapy in a patient with symptomatic sickle-cell disease using an arterio-venous fistula. Transfus Med 12 (2002) 75-77
20. Wanko S.O., and Telen M.J. Transfusion management in sickle cell disease. Hematol Oncol Clin North Am 19 (2005) 803-826
21. Valbonesi M., Giannini G., Morelli F., Frisoni R., and Capra C. Multi Component collection as of 2005. Transfus Apheresis Sci 32 3 (2005) 287-297
22. Aygun B., Padmanabhan S., Paley C., and Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 42 (2002) 37-43
23. Schonewille H., van de Watering L.M., Loomans D.S., and Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 46 2 (2006) 250-256
24. Redman M., Regan F., and Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 71 4 (1996) 216-220
25. Amrolia P.J., Almeida A., Halsey C., Roberts I.A.G., and Davies S. Therapeutic challenges in childhood sickle cell disease-part 2: a problem oriented approach. Rev Br J Haematol (2003) 725-736
26. Ware R.E., Zimmerman S.A., Sylvestre P.B., Mortier N.A., Davies J.S., Treem W.R., et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145 (2004) 346-352
27. Dobson S.R., Holden K.R., Nietert P.J., Cure J.K., Laver J.H., Disco D., et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99 (2002) 3144-3150
28. de Montalbert M., Brousse V., Elie C., Bernaudin F., Shi J., and Landais P. Long-term Hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 91 (2006) 125-128